RxDoctor Payments Data

Arifulla Khan

Psychiatry · Bellevue, WANPI 1134241888

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $940 of the $1,340 with a category attached, or 70.2%. Pfizer accounts for 70.2% of it on its own, with 2 other manufacturers making up the rest. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,340in general payments, 2019–2025

Across 9 payments — averaging $148.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$940
  • Eli Lilly$360
  • Genentech, Inc.$40
$35,896,250in research payments, 2019–2025

Across 2,353 payments — averaging $15,256 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$19.8M
  • AbbVie$4.4M
  • Sage Therapeutics, LLC$1.8M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.6M
  • Pfizer$1.1M
  • Alkermes, Inc.$969K
  • plus $6.2M from 30 others

What the payments were for

  • Speaking & faculty fees$94070%
  • Travel & lodging$15011%
  • Food & beverage$21016%
  • Education$403%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$940
Eli Lilly7$360
Genentech, Inc.1$40

How this compares

$1,340 in reported general payments places this provider in the 90th percentile of 576 psychiatry providers in Washington.

See all psychiatry providers in Washington →

Other psychiatry in Bellevue

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →